Gilead Sciences (NQ:GILD)

144.01 -0.73 (-0.50%)

Delayed Quote Updated: 1:50 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

78 79 Next >

Jefferies Names Akero Therapeutics, Scholar Rock As Biotech Companies With Takeover Potential, But Retail Isn’t Pleased ↗

June 13, 2025

Jefferies thinks big pharma companies are "still on the hunt" for deals.

Via Stocktwits

June 11, 2025

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can...

Via StockStory

Why Gilead Scinces Stock Tumbled on Tuesday ↗

June 10, 2025

Via The Motley Fool

Gelteq Stock Soars On Deal With Healthy Extracts For Product Distribution In North America: Retail Chatter Explodes ↗

June 10, 2025

The agreement names Healthy Extracts as Gelteq’s exclusive North American storage, shipping, and fulfillment partner.

Via Stocktwits

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today ↗

June 02, 2025

Via Benzinga

US FDA Places Clinical Hold On Gilead Trials Of Two Investigational HIV Treatments: Retail’s On The Fence ↗

June 10, 2025

The clinical hold is due to the identification of a safety signal, characterized by decreases in CD4+ T-cell (CD4) and absolute lymphocyte counts, in certain participants receiving the combination of...

Via Stocktwits

2 Reasons to Like GILD (and 1 Not So Much)

June 06, 2025

While the broader market has struggled with the S&P 500 down 2.4% since December 2024, Gilead Sciences has surged ahead as its stock price has climbed by 21% to $111.47 per share. This performance may...

Via StockStory

Topics Stocks

Gilead's HIV Pipeline Gains Traction With Upcoming FDA Decision For HIV-1 Drug ↗

June 05, 2025

Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S. PrEP users by 2035.

Via Benzinga

1 Healthcare Stock Worth Your Attention and 2 to Turn Down

June 03, 2025

Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, and over the past six...

Via StockStory

Topics Stocks

Kite Presents New Real-World Data Supporting Use of Potentially Curative Yescarta® in Outpatient Care Setting for Patients with Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025

June 01, 2025

From Gilead Sciences, Inc.

Via Business Wire

Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer

May 31, 2025

From Gilead Sciences, Inc.

Via Business Wire

BioLineRx Stock Jumps On Positive Data from Pilot Phase Of Pancreatic Cancer Drug Trial: Retail Cheers The ‘Buy’ Rating ↗

May 30, 2025

The company said that updated results from the pilot phase indicate that four of eleven patients remained disease progression-free after more than one year.

Via Stocktwits

Gilead Eyes HIV Drug Rollout In Low-Income Countries Despite Funding Uncertainty, Says Report: Retail Holds Onto Bearish Stance ↗

May 30, 2025

Gilead Chief Commercial Officer Johanna Mercier told Reuters that the company is eyeing a “global approach" to the launch of Lenacapavir.

Via Stocktwits

Topics Government

GILEAD SCIENCES INC (NASDAQ:GILD) – A Quality Stock Worth Considering ↗

May 30, 2025

GILEAD SCIENCES (NASDAQ:GILD) is a high-quality biopharma stock with strong profitability, efficient capital use, and attractive valuation, making it a candidate for long-term investors.

Via Chartmill

10 Health Care Stocks Whale Activity In Today's Session ↗

May 28, 2025

Via Benzinga

GILEAD SCIENCES INC (NASDAQ:GILD) – A Potentially Undervalued Biopharmaceutical Stock ↗

May 27, 2025

GILEAD SCIENCES (NASDAQ:GILD) appears undervalued with strong profitability, a solid dividend, and reasonable growth potential, making it a candidate for value investors.

Via Chartmill

ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors

May 23, 2025

From Gilead Sciences, Inc.

Via Business Wire

What Analysts Are Saying About Gilead Sciences Stock ↗

May 21, 2025

Via Benzinga

What's going on in today's session: S&P500 movers ↗

May 19, 2025

Curious about the top performers within the S&P500 index one hour before the close of the markets on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive...

Via Chartmill

Uncover the latest developments among S&P500 stocks in today's session. ↗

May 19, 2025

Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.

Via Chartmill

Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer at 2025 ASCO and EHA

May 15, 2025

From Gilead Sciences, Inc.

Via Business Wire

Is the Market Bullish or Bearish on Gilead Sciences? ↗

May 15, 2025

Via Benzinga

Thermo Fisher, Biogen, Gilead Sciences, Moderna, and QuidelOrtho Stocks Trade Up, What You Need To Know

May 12, 2025

A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides...

Via StockStory

Topics Government Stocks World Trade

Top S&P500 movers in Monday's pre-market session ↗

May 12, 2025

Stay updated with the S&P500 stocks that are on the move in today's pre-market session.

Via Chartmill

S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform ↗

May 12, 2025

It's still unclear how President Donald Trump plans to tie drug prices in the U.S. to international prices.

Via Investor's Business Daily

Topics Government Stocks

Wall Street Rips Higher As Tariff Truce Halts US–China Economic Escalation ↗

May 12, 2025

US-China agree to slash tariffs by over 100%, easing fears of economic slowdown and inflation. Markets cheer with futures rising and yields up.

Via Benzinga

Topics Economy World Trade

GILD Q1 Earnings Call: HIV Growth and Pipeline Momentum Offset Revenue Miss

May 12, 2025

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) missed Wall Street’s revenue expectations in Q1 CY2025, with sales flat year on year at $6.67 billion. The company’s full-year revenue guidance...

Via StockStory

2 High-Yield Dividend Stocks to Buy in May and Hold Forever ↗

May 10, 2025

Via The Motley Fool

Topics Intellectual Property

Market Monitor May 9 (Boeing, MicroStrategy UP - Match Group DOWN) ↗

May 09, 2025

U.S. stocks rally amid steady Fed rates, strong Disney and AMD earnings, but Alphabet falls on Apple concerns.

Via Chartmill

Topics Economy

3 Value Stocks with Mounting Challenges

May 09, 2025

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are...

Via StockStory

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

78 79 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.